コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ve an emerging role in assessing response to neoadjuvant therapy.
2 g nodal status and complete responders after neoadjuvant therapy.
3 ween 14 days and 6 weeks after completion of neoadjuvant therapy.
4 a novel means for evaluating prognosis after neoadjuvant therapy.
5 g nodal status and complete responders after neoadjuvant therapy.
6 of hepatocellular carcinoma and the role of neoadjuvant therapy.
7 a novel means for evaluating prognosis after neoadjuvant therapy.
8 CI, 44.1% to 78.4%) were node negative after neoadjuvant therapy.
9 blish a relatively high (28%) pCR rate after neoadjuvant therapy.
10 performed 4 to 10 weeks after completion of neoadjuvant therapy.
11 predictor of pathologic response to initial neoadjuvant therapy.
12 d levels of ER phosphorylation when given as neoadjuvant therapy.
13 clinically useful predictors of pCR to T/FAC neoadjuvant therapy.
14 A minority (17.0%) had neoadjuvant therapy.
15 cal failure, who are in need of an effective neoadjuvant therapy.
16 e most important prognostic indicators after neoadjuvant therapy.
17 ith high-risk features and respond poorly to neoadjuvant therapy.
18 Four (14%) had received prior adjuvant or neoadjuvant therapy.
19 e may increase the probability of completing neoadjuvant therapy.
20 py, and prior to surgery after completion of neoadjuvant therapy.
21 esection, of whom 88.8% received any form of neoadjuvant therapy.
22 uch as stage, tumor location, and receipt of neoadjuvant therapy.
23 to high-risk patients who have not received neoadjuvant therapy.
24 r patients according to their sensitivity to neoadjuvant therapy.
25 rline received FOLFIRINOX and 87 received no neoadjuvant therapy.
26 on within HER2-positive breast cancer during neoadjuvant therapy.
27 idual patients with breast cancer undergoing neoadjuvant therapy.
28 ase and delivering effective adjuvant and/or neoadjuvant therapy.
29 Thirty-five of 38 patients (92%) completed neoadjuvant therapy.
30 inked to age, diabetes, cardiac disease, and neoadjuvant therapy.
31 long-term benefit of trastuzumab-containing neoadjuvant therapy.
32 otable in terms of assessment of response to neoadjuvant therapy.
33 resection for rectal cancer with or without neoadjuvant therapy.
34 ar period, tumor stage, tumor histology, and neoadjuvant therapy.
35 sectable ICCA using a combination of OLT and neoadjuvant therapy.
36 nosis" stage III with selective avoidance of neoadjuvant therapy.
37 Three of them underwent neoadjuvant therapy.
38 achievable in patients with RC treated with neoadjuvant therapy.
39 fy target pathways that may be exploited for neoadjuvant therapies.
41 chemotherapeutics is being tested as part of neoadjuvant therapy after resection or loco-regional the
42 e have included chemoembolization before and neoadjuvant therapy after surgery, neither of which has
44 iopsy-confirmed metastasis before initiating neoadjuvant therapy allows for evaluation of response in
45 he addition of bevacizumab, as compared with neoadjuvant therapy alone, was associated with a higher
46 patients underwent surgical resection after neoadjuvant therapy and had pathologic assessment of tum
47 ent of HTV after CRT is based on response to neoadjuvant therapy and has been shown to correlate with
48 pathologic complete response rates (pCRs) to neoadjuvant therapy and improve progression-free surviva
50 up analysis of T1 and T2 rectal cancer after neoadjuvant therapy and local excision showed oncologica
51 ET/CT in the assessment of early response to neoadjuvant therapy and of response to therapy for metas
52 ediastinum and around the celiac trunk after neoadjuvant therapy and resection does not alter the TNM
53 using on the role of OLT in combination with neoadjuvant therapy and risk stratification of patients
54 d was compared between patients who received neoadjuvant therapy and surgery (NEO) and patients who u
57 y to be treated at academic centers, receive neoadjuvant therapy, and have higher T-stage and longer
58 predicted response to fluoropyrimidine-based neoadjuvant therapy, and implications of germline altera
59 fter controlling for comorbidity, receipt of neoadjuvant therapy, and nodal involvement, a longer sur
61 iation of patient and tumor characteristics, neoadjuvant therapy, and operative factors with postoper
62 d tumor cells (DTC) that survive adjuvant or neoadjuvant therapy, and patients with detectable DTCs f
64 stages I to III HER2-positive breast cancer, neoadjuvant therapy, and reports of both pCR and an even
66 ge, tumor stage, previous abdominal surgery, neoadjuvant therapy, and surgical radicality did not inf
67 sponse (TRG 1) defines a unique cohort after neoadjuvant therapy, associated closely with nodal respo
69 the long-term overall effects on survival of neoadjuvant therapy before surgery or radiation are unkn
71 ients receiving neoadjuvant FOLFIRINOX or no neoadjuvant therapy between April 2011 and February 2014
72 geal cancer treated by esophagectomy without neoadjuvant therapy between January 1988 and December 20
73 ell tolerated and beneficial as adjuvant and neoadjuvant therapy, but its utility in these settings c
74 nt and adjuvant therapies and surgery alone, neoadjuvant therapies combined with surgery compared wit
77 e randomly assigned 1206 patients to receive neoadjuvant therapy consisting of docetaxel (100 mg per
78 n of an aging population, recent advances in neoadjuvant therapies, data supporting the oncologic eff
81 multivariable analysis, when controlling for neoadjuvant therapy, distance of tumor from anal verge,
82 o not achieve a pCR might still benefit from neoadjuvant therapy enabling breast-conserving surgery.
83 ancer received GLN (0.5 g/kg/day) during MTX neoadjuvant therapy, escalating from doses of 40 mg/m2 t
86 nt-free survival from trastuzumab-containing neoadjuvant therapy followed by adjuvant trastuzumab in
87 most recent outcomes of a protocol involving neoadjuvant therapy followed by liver transplant for hil
88 ent recent data demonstrating the success of neoadjuvant therapy followed by liver transplantation fo
90 lar cholangiocarcinoma who were treated with neoadjuvant therapy followed up by liver transplantation
91 ents with perihilar cholangiocarcinoma using neoadjuvant therapy, followed by liver transplantation,
93 age range, 45-70 years) scheduled to undergo neoadjuvant therapy for breast cancer underwent ultrason
94 orelbine, and trastuzumab is a highly active neoadjuvant therapy for HER2-overexpressing locally adva
95 and overall survival in patients who receive neoadjuvant therapy for high-grade extremity soft tissue
96 al, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-risk clinical stage II or I
97 f docetaxel, vinorelbine, and trastuzumab as neoadjuvant therapy for human epidermal growth factor re
99 erial catheters/pumps and may have a role as neoadjuvant therapy for liver metastases that are unrese
102 , well-tolerated, and efficacious regimen as neoadjuvant therapy for patients with squamous cell carc
103 rderline resectable PC and, at some centers, neoadjuvant therapy has been extended to patients with r
104 demonstrated that single-agent paclitaxel as neoadjuvant therapy has significant antitumor activity,
105 maging modalities, and the widespread use of neoadjuvant therapy have all contributed to these improv
106 odel, prevented metastatic disease following neoadjuvant therapy in a triple-negative mammary carcino
107 -3 and similar drugs could be candidates for neoadjuvant therapy in cancers with a functional p53.
108 ts of letrozole plus lapatinib or placebo as neoadjuvant therapy in hormone receptor (HR) -positive/h
111 studied during the last decade with various neoadjuvant therapies including chemotherapy and combina
113 g that grades III to IV toxic effects during neoadjuvant therapy increase POM has significant implica
120 ronous disease should be dealt with; whether neoadjuvant therapy is useful or harmful for these patie
121 rapy and/or chemoradiation prior to surgery (neoadjuvant therapy) is increasingly recognized as the p
123 Despite important progress in adjuvant and neoadjuvant therapies, metastatic disease often develops
124 erall survival between patients who received neoadjuvant therapy (NAT) followed by resection and thos
125 ic leakage at any time during follow-up were neoadjuvant therapy (odds ratio 2.85; 95% confidence int
128 tential role of FDG-PET in the monitoring of neoadjuvant therapy of soft-tissue and musculoskeletal s
129 We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for
130 ith respect to medical comorbidities, use of neoadjuvant therapy, operative outcomes, postoperative c
133 f success in a confirmatory phase 3 trial of neoadjuvant therapy reached a prespecified threshold for
137 igated as emerging techniques for evaluating neoadjuvant therapy response for patients with primary b
142 stology and residual nodal involvement after neoadjuvant therapy, the risk of brain metastases was 53
143 n tumor accumulation of FDG during and after neoadjuvant therapy; these changes are dependent on the
145 l, tumor marker and pathological response to neoadjuvant therapy, time to recurrence, patterns of fai
146 t adjuvants to surgical resection, including neoadjuvant therapy to downstage tumors prior to planned
147 to determine whether PVE can be used during neoadjuvant therapy to enhance growth of future residual
148 al verge were randomized after completion of neoadjuvant therapy to laparoscopic or open resection.
150 ession, adjusted for age, sex, co-morbidity, neoadjuvant therapy, tumour stage, tumour histology, sur
155 e-intensive and time-intensive multimodality neoadjuvant therapy was successfully administered to a m
156 able site of EHD, and progression of CRLM on neoadjuvant therapy were associated with overall surviva
157 able site of EHD, and progression of CRLM on neoadjuvant therapy were associated with overall surviva
158 changes in (18)F-fluciclovine avidity after neoadjuvant therapy were compared to breast cancer thera
160 o underwent complete gross resection without neoadjuvant therapy were identified from a prospectively
161 y with en bloc 2-field lymphadenectomy after neoadjuvant therapy were included, and survival was anal
162 with soft-tissue sarcomas who had undergone neoadjuvant therapy were reviewed by two readers during
165 been further evaluated, both as adjuvant and neoadjuvant therapy with radiation therapy or radical pr
166 (P = 0.02) from 16% at diagnosis to 31% post-neoadjuvant therapy, with loss of LBM (-3.0 +/- 5.4 kg,
167 ches combined terms for "breast cancer" and "neoadjuvant therapy," with no limit on publication date.
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。